J&J scores approval for Rybrevant combo in first-line lung cancer, stoking rivalry with Tagrisso

Johnson & Johnson scored a label expansion for Rybrevant in combination with the newly-approved Lazcluze to treat certain first-line lung cancer patients, putting it in …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Children’s wellbeing affected by the lingering effects of COVID-19 pandemic

While COVID-19 lockdowns are no longer mandated, the stress and anxiety of the pandemic still lingers, especially among young South Australians, say health experts at

August 25, 2023

Study examines what hinders and what promotes healthy sexual behaviors among university students

A study by the UOC in partnership with several Chilean universities examines the difficulties university students face regarding sexual health issues, and proposes specific measures

September 15, 2023

ArriVent inks ADC deal with Alphamab; Annexon’s $125M offering

Plus, news about Equillium and Structure Therapeutics: ArriVent, Alphamab team up on multi-ADC collab: The companies will work together to develop … Sign up to

June 6, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.